Multicenter randomized phase II study of docetaxel (Doc) given q3w vs q1w plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracyclin pretreated metastatic breast cancer (MBC).
BREAST CANCER RESEARCH AND TREATMENT（2002）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要